Journal Article
. 2017 Apr;164(1).
doi: 10.1007/s10549-017-4234-4.

MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer

Jinil Han 1 Yoon-La Choi 2 Haein Kim 3 Jun Young Choi 3 Se Kyung Lee 4 Jeong Eon Lee 5 Joon-Seok Choi 6 Sarah Park 7 Jong-Sun Choi 7 Young Deug Kim 8 Seok Jin Nam 4 Byung-Ho Nam 9 Mi Jeong Kwon 10 Young Kee Shin 11 
  • PMID: 28409241
  •     41 References
  •     11 citations


Purpose: More accurate prediction of patient outcome based on molecular subtype is required to identify patients who will benefit from specific treatments.

Methods: We selected novel 16 candidate prognostic genes, including 10 proliferation-related genes (p-genes) and 6 immune response-related genes (i-genes), from the gene list identified in our previous study. We then analyzed the association between their expression, measured by quantitative real-time reverse transcription-PCR in formalin-fixed, paraffin-embedded tissues, and clinical outcome in 819 breast cancer patients according to molecular subtype.

Results: The prognostic significance of clinical and gene variables varied according to the molecular subtype. Univariate analysis showed that positive lymph node status was significantly correlated with the increased risk of distant metastasis in all subtypes except the hormone receptor-negative, HER2-positive (HR-/HER2+) subtype. Most p-genes were significantly associated with poor prognosis in patients with the HR+/HER2- subtype, whereas i-genes correlated with a favorable outcome in patients with HR-/HER2+ breast cancer. In HR-/HER2+ breast cancer, four genes (three i-genes BTN3A2, CD2, and TRBC1 and the p-gene MMP11) were significantly associated with distant metastasis-free survival (DMFS). A new prognostic model for HR-/HER2+ breast cancer based on the expression of MMP11 and CD2 was developed and the DMFS for patients in the high-risk group according to our model was significantly lower than that for those in the low-risk group. Multivariate analyses revealed that our risk score is an independent prognostic factor for DMFS. Moreover, C-index showed that our risk score has a superior prognostic performance to traditional clinicopathological factors.

Conclusions: Our new prognostic model for HR-/HER2+ breast cancer provides more accurate information on the risk of distant metastasis than traditional clinical prognostic factors and may be used to identify patients with a good prognosis in this aggressive subtype of breast cancer.

Keywords: Breast cancer; HER2-positive (HR−/HER2+) breast cancer; Hormone receptor-negative; Immune response-related genes (i-genes); Prognostic model; Proliferation-related genes (p-genes); Risk of distant metastasis.

Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
A S Coates, E P Winer, +6 authors, Panel Members.
Ann Oncol, 2015 May 06; 26(8). PMID: 25939896    Free PMC article.
Highly Cited.
Critical Role of CD2 Co-stimulation in Adaptive Natural Killer Cell Responses Revealed in NKG2C-Deficient Humans.
Lisa L Liu, Johannes Landskron, +15 authors, Vivien Béziat.
Cell Rep, 2016 Apr 28; 15(5). PMID: 27117418    Free PMC article.
Highly Cited.
PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer.
Gordon C Wishart, Elizabeth M Azzato, +5 authors, Paul D P Pharoah.
Breast Cancer Res, 2010 Jan 08; 12(1). PMID: 20053270    Free PMC article.
A strategy to build and validate a prognostic biomarker model based on RT-qPCR gene expression and clinical covariates.
Maud Tournoud, Audrey Larue, +5 authors, Jean-Baptiste Veyrieras.
BMC Bioinformatics, 2015 Apr 17; 16. PMID: 25880752    Free PMC article.
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Mitch Dowsett, Ivana Sestak, +7 authors, Jack Cuzick.
J Clin Oncol, 2013 Jul 03; 31(22). PMID: 23816962
Highly Cited.
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.
Douglas G Altman, Lisa M McShane, Willi Sauerbrei, Sheila E Taube.
PLoS Med, 2012 Jun 08; 9(5). PMID: 22675273    Free PMC article.
Highly Cited.
An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk.
Christina Yau, John Sninsky, +9 authors, Christopher C Benz.
Breast Cancer Res, 2013 Nov 01; 15(5). PMID: 24172169    Free PMC article.
Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.
F E Harrell, K L Lee, D B Mark.
Stat Med, 1996 Feb 28; 15(4). PMID: 8668867
Highly Cited. Review.
Supervised risk predictor of breast cancer based on intrinsic subtypes.
Joel S Parker, Michael Mullins, +17 authors, Philip S Bernard.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204204    Free PMC article.
Highly Cited.
PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2.
G C Wishart, C D Bajdik, +34 authors, P D P Pharoah.
Br J Cancer, 2012 Aug 02; 107(5). PMID: 22850554    Free PMC article.
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Martin Filipits, Margaretha Rudas, +25 authors, EP Investigators.
Clin Cancer Res, 2011 Aug 03; 17(18). PMID: 21807638
Highly Cited.
Gene expression profiling predicts clinical outcome of breast cancer.
Laura J van 't Veer, Hongyue Dai, +13 authors, Stephen H Friend.
Nature, 2002 Feb 02; 415(6871). PMID: 11823860
Highly Cited.
The impact of primary tumor size, lymph node status, and other prognostic factors on the risk of cancer death.
L Leon Chen, Matthew E Nolan, +6 authors, James S Michaelson.
Cancer, 2009 Aug 07; 115(21). PMID: 19658184
High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates.
Gabriela Alexe, Gul S Dalgin, +9 authors, Gyan Bhanot.
Cancer Res, 2007 Nov 17; 67(22). PMID: 18006808
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer.
Andrew E Teschendorff, Ahmad Miremadi, +2 authors, Carlos Caldas.
Genome Biol, 2007 Aug 09; 8(8). PMID: 17683518    Free PMC article.
Highly Cited.
Repeated observation of breast tumor subtypes in independent gene expression data sets.
Therese Sorlie, Robert Tibshirani, +13 authors, David Botstein.
Proc Natl Acad Sci U S A, 2003 Jun 28; 100(14). PMID: 12829800    Free PMC article.
Highly Cited.
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.
Torsten O Nielsen, Joel S Parker, +12 authors, Matthew J Ellis.
Clin Cancer Res, 2010 Sep 15; 16(21). PMID: 20837693    Free PMC article.
Highly Cited.
Stromelysin-3 over-expression enhances tumourigenesis in MCF-7 and MDA-MB-231 breast cancer cell lines: involvement of the IGF-1 signalling pathway.
Grit Kasper, Matthias Reule, +7 authors, Kerstin E Lehmann.
BMC Cancer, 2007 Jan 20; 7. PMID: 17233884    Free PMC article.
Breast cancer classification and prognosis based on gene expression profiles from a population-based study.
Christos Sotiriou, Soek-Ying Neo, +7 authors, Edison T Liu.
Proc Natl Acad Sci U S A, 2003 Aug 15; 100(18). PMID: 12917485    Free PMC article.
Highly Cited.
A prognostic index in primary breast cancer.
J L Haybittle, R W Blamey, +5 authors, K Griffiths.
Br J Cancer, 1982 Mar 01; 45(3). PMID: 7073932    Free PMC article.
Highly Cited.
On non-detects in qPCR data.
Matthew N McCall, Helene R McMurray, Hartmut Land, Anthony Almudevar.
Bioinformatics, 2014 Apr 26; 30(16). PMID: 24764462    Free PMC article.
A prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunity.
Ensel Oh, Yoon-La Choi, +3 authors, Young Kee Shin.
Breast Cancer Res Treat, 2011 Jun 15; 132(2). PMID: 21667120
Clinical significance of CD151 overexpression in subtypes of invasive breast cancer.
M J Kwon, S Park, +9 authors, Y-L Choi.
Br J Cancer, 2012 Feb 02; 106(5). PMID: 22294188    Free PMC article.
Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers.
Julia Y S Tsang, Suen-Wah Hui, +5 authors, Gary M Tse.
Breast Cancer Res Treat, 2013 Nov 26; 143(1). PMID: 24272079
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Gli1 enhances migration and invasion via up-regulation of MMP-11 and promotes metastasis in ERα negative breast cancer cell lines.
Yeon-Jin Kwon, Douglas R Hurst, +4 authors, Andra R Frost.
Clin Exp Metastasis, 2011 Mar 29; 28(5). PMID: 21442356    Free PMC article.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.
Achim Rody, Uwe Holtrich, +10 authors, Manfred Kaufmann.
Breast Cancer Res, 2009 Mar 11; 11(2). PMID: 19272155    Free PMC article.
Highly Cited.
Systems biology and genomics of breast cancer.
Charles M Perou, Anne-Lise Børresen-Dale.
Cold Spring Harb Perspect Biol, 2010 Nov 05; 3(2). PMID: 21047916    Free PMC article.
Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival.
Yoon-La Choi, Ensel Oh, +12 authors, Young Kee Shin.
BMC Cancer, 2010 Sep 24; 10. PMID: 20860845    Free PMC article.
Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
Johan Staaf, Markus Ringnér, +15 authors, Ake Borg.
J Clin Oncol, 2010 Mar 17; 28(11). PMID: 20231686
A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.
Christina Yau, Laura Esserman, +3 authors, Christopher C Benz.
Breast Cancer Res, 2010 Oct 16; 12(5). PMID: 20946665    Free PMC article.
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
Christina Curtis, Sohrab P Shah, +29 authors, Samuel Aparicio.
Nature, 2012 Apr 24; 486(7403). PMID: 22522925    Free PMC article.
Highly Cited.
A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer.
Andrew E Teschendorff, Carlos Caldas.
Breast Cancer Res, 2008 Aug 30; 10(4). PMID: 18755024    Free PMC article.
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.
Ethan Cerami, Jianjiong Gao, +12 authors, Nikolaus Schultz.
Cancer Discov, 2012 May 17; 2(5). PMID: 22588877    Free PMC article.
Highly Cited.
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.
Christine Desmedt, Benjamin Haibe-Kains, +6 authors, Christos Sotiriou.
Clin Cancer Res, 2008 Aug 14; 14(16). PMID: 18698033
Highly Cited.
MicroRNA miR-98 inhibits tumor angiogenesis and invasion by targeting activin receptor-like kinase-4 and matrix metalloproteinase-11.
Vinayakumar Siragam, Zina Jeyapalan Rutnam, +8 authors, Burton B Yang.
Oncotarget, 2012 Dec 06; 3(11). PMID: 23211491    Free PMC article.
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, +14 authors, A L Børresen-Dale.
Proc Natl Acad Sci U S A, 2001 Sep 13; 98(19). PMID: 11553815    Free PMC article.
Highly Cited.
Matrix metalloproteinase-11 overexpressed in lobular carcinoma cells of the breast promotes anoikis resistance.
Tamotsu Takeuchi, Yoshihiro Adachi, Tomoko Nagayama, Mutsuo Furihata.
Virchows Arch, 2011 Jul 21; 459(3). PMID: 21773755
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Lisa A Carey, Charles M Perou, +14 authors, Robert C Millikan.
JAMA, 2006 Jun 08; 295(21). PMID: 16757721
Highly Cited.
High expression of NR1D1 is associated with good prognosis in triple-negative breast cancer patients treated with chemotherapy.
Hyelin Na, Jinil Han, +4 authors, Mi-Ock Lee.
Breast Cancer Res, 2019 Nov 30; 21(1). PMID: 31779659    Free PMC article.
UBE2C Overexpression Aggravates Patient Outcome by Promoting Estrogen-Dependent/Independent Cell Proliferation in Early Hormone Receptor-Positive and HER2-Negative Breast Cancer.
Yu-Jin Kim, Gyunghwa Lee, +4 authors, Young Kee Shin.
Front Oncol, 2020 Feb 11; 9. PMID: 32039034    Free PMC article.
Diagnosis of triple negative breast cancer based on radiomics signatures extracted from preoperative contrast-enhanced chest computed tomography.
Qingliang Feng, Qiang Hu, +2 authors, Ziyi Yin.
BMC Cancer, 2020 Jun 24; 20(1). PMID: 32571245    Free PMC article.
Matrix Metalloproteinase 11 Is a Potential Therapeutic Target in Lung Adenocarcinoma.
Haoran Yang, Peng Jiang, +7 authors, Wulin Yang.
Mol Ther Oncolytics, 2019 Apr 27; 14. PMID: 31024988    Free PMC article.
An integrated bioinformatics analysis of potential therapeutic targets among matrix metalloproteinases in breast cancer.
Haiqun Xia, Weixuan Yu, +4 authors, Yunda Zhang.
Oncol Lett, 2019 Aug 28; 18(3). PMID: 31452777    Free PMC article.
Identification of gene modules associated with survival of diffuse large B-cell lymphoma treated with CHOP-based chemotherapy.
YongChao Gao, Bao Sun, +5 authors, Wei Zhang.
Pharmacogenomics J, 2020 Feb 12; 20(5). PMID: 32042095    Free PMC article.
Isobaric Tags for Relative and Absolute Quantitation in Proteomic Analysis of Potential Biomarkers in Invasive Cancer, Ductal Carcinoma In Situ, and Mammary Fibroadenoma.
Hao Wu, Xian-Yu Zhang, +7 authors, Da Pang.
Front Oncol, 2020 Nov 17; 10. PMID: 33194682    Free PMC article.
A novel immune prognostic index for stratification of high-risk patients with early breast cancer.
Hannah Lee, Mi Jeong Kwon, +3 authors, Young Kee Shin.
Sci Rep, 2021 Jan 10; 11(1). PMID: 33420250    Free PMC article.
Screening of a Novel Upregulated lncRNA, A2M-AS1, That Promotes Invasion and Migration and Signifies Poor Prognosis in Breast Cancer.
Kai Fang, Hu Caixia, +2 authors, Lihua Li.
Biomed Res Int, 2020 May 01; 2020. PMID: 32352014    Free PMC article.
Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer.
Hsing-Ju Wu, Pei-Yi Chu.
Int J Mol Sci, 2021 Jan 14; 22(2). PMID: 33435254    Free PMC article.
A Competing Endogenous RNA Network Reveals Novel lncRNA, miRNA and mRNA Biomarkers With Diagnostic and Prognostic Value for Early Breast Cancer.
Zhong-Bing Luo, Gui-E Lai, +3 authors, Feng-En Liu.
Technol Cancer Res Treat, 2020 Dec 30; 19. PMID: 33371806    Free PMC article.